New research finds that non-dividing colon cancer cells use altered glucose metabolism to ward off accumulation of toxic reactive oxidative species.
- A recent study demonstrates that magnetic resonance imaging (MRI) and artificial intelligence (AI) can be used to detect early signs of tumor cell death in response to a novel virus-based cancer therapy.
- Researchers used quantitative molecular MRI images to measure multiple tissue properties that are altered with cell-death.
- Future investigation of this approach in human brain tumor patients would help to optimize virus-based therapies.
Or Perlman, PhD
This study demonstrates the strength and promise of implementing computerized AI-based technology in medicine for the noninvasive investigation of biological processes that underlie disease.
Research Fellow, Athinoula A. Martinos Center for Biomedical Imaging
BOSTON – In a recent study published in Nature Biomedical Engineering, a team led by researchers at Massachusetts General Hospital (MGH) has demonstrated that magnetic resonance imaging (MRI) and artificial intelligence (AI) can be used to detect early signs of tumor cell death in response to a novel virus-based cancer therapy.
Recently, a promising therapeutic virus that selectively kills cancer cells while sparing normal tissue has sparked hope for treating aggressive brain tumors. To further optimize the virus-based therapy, frequent non-invasive monitoring of the treatment response must be performed. This monitoring is crucial for understanding the interactions between the virus and cancer cells, such as the extent of virus spread within the tumor and therapeutic response.
The researchers used quantitative molecular MRI images to measure multiple tissue properties, including tissue pH and protein concentration, that are altered with cell-death. This method allows therapeutic response monitoring much earlier than with previous techniques. The treatment responses were visible just 48 hours after viral-therapy, long before any changes in tumor volume were observed.
“We programmed an MRI scanner to create unique signal “fingerprints” for different molecular compounds and cellular pH. A deep learning neural network was then used to decode the fingerprints and generate quantitative pH and molecular maps,” says Christian Farrar, PhD, an investigator and faculty at the Athinoula A. Martinos Center for Biomedical Imaging. “The MRI molecular fingerprinting method was validated in a mouse brain tumor study where the tumors were treated with a novel virus-based therapy that selectively killed cancer cells.”
To maximize the efficiency of this treatment approach, the researchers developed a method for the detection of tumor cell death caused by the virus. This has allowed for the early and rapid detection of treatment-responsive tumor regions. Recently, the researchers have implemented this method to quantify cellular pH and molecular compounds in the healthy human brain. Future investigation of this approach in human brain tumor patients would help to optimize these virus-based therapies
“This study demonstrates the strength and promise of implementing computerized AI-based technology in medicine for the noninvasive investigation of biological processes that underlie disease,” says Or Perlman,PhD, a research fellow at the Athinoula A. Martinos Center for Biomedical Imaging. “One of the most interesting and key components for the success of this approach was the use of simulated molecular fingerprints to train the machine learning neural network. This concept could potentially be expanded and investigated for solving other medical and scientific challenges.”
This study describes a new method for detecting tumor cell death non-invasively using MRI. The capacity to do this could be useful for non-invasive monitoring of cancer treatment, potentially improving patient care and tailoring the treatment to an individual patient. The same approach might also be beneficial for detecting and characterizing other medical conditions where elevated cell death occurs, such as stroke and liver disease. While the study was mainly validated using a mouse brain tumor model, the researchers have demonstrated the ability to use the same method for producing quantitative pH and molecular maps in rat stroke models and healthy humans. In the future, they plan to further explore the applicability of this non-invasive imaging approach in patients with brain tumors and stroke.
The work was supported by the US National Institutes of Health and received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 836752 This paper reflects only the authors’ view, and the European Research Executive Agency is not responsible for any use that may be made of the information it contains
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals."
Related News and Articles
- Press Release
- Feb | 22 | 2022
Placebo effect activates same brain circuits targeted by brain-stimulation therapy for depression.
- Press Release
- Dec | 13 | 2021
A predictive model based on magnetic resonance spectroscopy can detect lung cancer from alterations in blood metabolites.
- Press Release
- Nov | 9 | 2021
Leave policies for residents and fellows have improved, but continued evaluation and innovation are needed
Researchers at Mass General/Brigham found that specialty medical board policies remain variable and that policy clarifications could reduce confusion around leave taking
- Press Release
- Nov | 1 | 2021
Recent study verifies technique’s potential in patients with atrial fibrillation.
- Press Release
- Aug | 30 | 2021
Unsupervised AI breaks new ground by predicting the progression of COVID-19 and survival of patients directly from their chest CT images
A multi-center study showed that unsupervised deep learning based on computed tomography can provide a significantly higher prognostic performance than established laboratory tests and existing image-based visual and quantitative survival predictors